Current and emerging therapies for the management of functional gastrointestinal disorders

被引：6

作者：

Craig, Orla F. ^{[1
]}

Quigley, Eamonn M. M. ^{[1
,2
]}

机构：

[1] Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland

[2] Cork Univ Hosp, Dept Med, Clin Sci Bldg, Cork, Ireland

来源：

THERAPEUTIC ADVANCES IN CHRONIC DISEASE | 2011年 / 2卷 / 02期

基金：

爱尔兰科学基金会;

关键词：

antibiotics; antidepressants; cognitive behavioural therapy; functional dyspepsia; functional gastrointestinal disorders; functional heartburn; irritable bowel syndrome; probiotics; serotonin;

D O I：

10.1177/2040622310389507

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The functional gastrointestinal disorders are common disorders that are associated with significant quality-of-life impairment and considerable economic burden on the healthcare system. They are frequently associated with a comorbid psychiatric condition; this, together with a striking lack of effective pharmacological therapies, means they represent a considerable therapeutic challenge to the treating physician. In this overview, we examine the evidence to support the use of agents currently used in the management of the more common functional gastrointestinal disorders and review emerging therapies.

引用

页码：87 / 99

页数：13

共 110 条

[1] Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite [J].

Akamizu, Takashi ;

Iwakura, Hiroshi ;

Ariyasu, Hiroyuki ;

Hosoda, Hiroshi ;

Murayama, Toshinori ;

Yokode, Masayuki ;

Teramukai, Satoshi ;

Seno, Hiroshi ;

Chiba, Tsutomu ;

Noma, Shunichi ;

Nakai, Yoshikatsu ;

Fukunaga, Mikhiko ;

Nakai, Yoshihide ;

Kangawa, Kenji .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (04) :491-498

[2] Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting [J].

Akehurst, RL ;

Brazier, JE ;

Mathers, N ;

O'Keefe, C ;

Kaltenthaler, E ;

Morgan, A ;

Platts, M ;

Walters, SJ .

PHARMACOECONOMICS, 2002, 20 (07) :455-462

[3] Lubiprostone: A chloride channel activator for treatment of chronic constipation [J].

Ambizas, Emily M. ;

Ginzburg, Regina .

ANNALS OF PHARMACOTHERAPY, 2007, 41 (06) :957-964

[4] Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome [J].

Andresen, Viola ;

Camilleri, Michael ;

Busciglio, Irene A. ;

Grudell, April ;

Burton, Duane ;

Mckinzie, Sanna ;

Foxx-Orenstein, Amy ;

Kurtz, Caroline B. ;

Sharma, Vineeta ;

Johnston, Jeffrey M. ;

Currie, Mark G. ;

Zinsmeister, Alan R. .

GASTROENTEROLOGY, 2007, 133 (03) :761-768

[5] THE EFFECT OF COARSE WHEAT BRAN IN THE IRRITABLE BOWEL SYNDROME - A DOUBLE-BLIND CROSSOVER STUDY [J].

ARFFMANN, S ;

ANDERSEN, JR ;

HEGNHOJ, J ;

DEMUCKADELL, OBS ;

MOGENSEN, NB ;

KRAG, E .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1985, 20 (03) :295-298

[6] Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial [J].

Atkinson, W ;

Sheldon, TA ;

Shaath, N ;

Whorwell, PJ .

GUT, 2004, 53 (10) :1459-1464

[7]

Aziz Q, 2000, J NEUROSCI, V20, P2657

[8] Aminosalicylates and Other Anti-Inflammatory Compounds for Irritable Bowel Syndrome [J].

Barbara, Giovanni ;

Stanghellini, Vincenzo ;

Cremon, Cesare ;

De Giorgio, Roberto ;

Fronzoni, Lucia ;

Serra, Mauro ;

Corinaldesi, Roberto .

DIGESTIVE DISEASES, 2009, 27 :115-121

[9] Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia [J].

Barbera, R ;

Feinle, C ;

Read, NW .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1995, 7 (11) :1051-1057

[10] An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome [J].

Brandt, Lawrence J. ;

Chey, William D. ;

Foxx-Orenstein, Amy E. ;

Quigley, Eamonn M. M. ;

Schiller, Lawrence R. ;

Schoenfeld, Philip S. ;

Spiegel, Brennan M. ;

Talley, Nicholas J. ;

Moayyedi, Paul .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 :S1-S36

← 1 2 3 4 5 6 7 8 9 10 →